SEARCH

SEARCH BY CITATION

References

  • Advani, R., Rosenberg, S.A. & Horning, S.J. (2004) Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. Journal of Clinical Oncology, 22, 14541459.
  • Al-Tourah, A.J., Gill, K.K., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. Journal of Clinical Oncology., 26, 51655169.
  • Apostolidis, J., Gupta, R.K., Grenzelias, D., Johnson, P.W., Pappa, V.I., Summers, K.E., Salam, A., Adams, K., Norton, A.J., Amess, J.A., Matthews, J., Bradburn, M., Lister, T.A. & Rohatiner, A.Z. (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. Journal of Clinical Oncology, 18, 527536.
  • Ardeshna, K.M. (2007) Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value. Core Evidence, 30, 121129.
  • Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Hudson, G., Linch, D.C. & British National Lymphoma Investigation. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. The Lancet, 362, 516522.
  • Ardeshna, K.M., Qian, W., Smith, P., Warden, J., Stevens, L., Pocock, C.F.E., Miall, F., Cunningham, D., Davies, J., Walewski, J., Ferhanoglu, A.B., Bradstock, K. & Linch, D.C. (2010) An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis blood. ASH Annual Meeting Abstracts , 116, 6.
  • Artz, A.S., Somerfield, M.R., Feld, J.J., Giusti, A.F., Kramer, B.S., Sabichi, A.L., Zon, R.T. & Wong, S.L. (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. Journal of Clinical Oncology., 28, 31993202.
  • Bastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G., Dumontet, C., Bryon, P.A. & Coiffier, B. (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. Journal of Clinical Oncology, 15, 15871594.
  • Bosga-Bouwer, A.G., Haralambieva, E., Booman, M., Boonstra, R., Van Den Berg, A., Schuuring, E., Van Den Berg, E., Kluin, P. & Poppema, S. (2005) BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B. Genes Chromosomes Cancer, 44, 301304.
  • Bosga-Bouwer, A.G., Van Berg Den, A., Haralambieve, E., De Jong, D., Boonstra, R., Kluin, P., Van Berg Den, E. & Poppema, S. (2006) Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Human Pathology, 37, 528533.
  • Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Céligny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 15, 11101117.
  • Brice, P., Simon, D., Bouabdallah, R., Bélanger, C., Haïoun, C., Thieblemont, C., Tilly, H., Harousseau, J.L., Doyen, C., Martin, C., Brousse, N., Solal- Céligny, P.H. & Groupe d’Etude des Lymphomes de l’Adulte (GELA). (2000) High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Annals of Oncology, 11, 15851590.
  • Brill, N.E., Baehr, G. & Rosenthal, N. (1925) Generalized giant follicle hyperplasia of lymph nodes and spleen. A hitherto undescribed type. Journal of the American Medical Association, 84, 668671.
  • Burton, C., Ell, P. & Linch, D. (2004) The role of PET imaging in lymphoma. British Journal of Haematology, 126, 772784.
  • Buske, C., Hoster, E., Dreyling, M., Hasford, J., Unterhalt, M. & Hiddemann, W. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood, 108, 15041508.
  • Cameron, D.A., Leonard, R.C., Mao, J.H. & Prescott, R.J. (1993) Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leukemia and Lymphoma, 10, 8999.
  • Cave, J., Edwards, S.G., Miller, R.F., Ardeshna, K.M. & Lee, S.M. (2009) Should we implement ‘opt-out’ HIV testing for patients with lymphoma? Clinical Medicine, 9, 320322.
  • Coiffier, B., Bouaffia, F., Thieblemont, C., Hequet, O., Arnaud, P. & Dumontet, C. (2002) Rituximab re-treatment in B-cell lymphoma patients. Blood, 100, a1390. (abstract)
  • Conlan, M.G., Bast, M., Armitage, J.O. & Weisenburger, D.D. (1990) Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. Journal of Clinical Oncology, 8, 11631172.
  • Czuczman, M.S., Emmanouilides, C., Darif, M., Witzig, T.E., Gordon, L.I., Revell, S., Vo, K. & Molina, A. (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. Journal of Clinical Oncology, 25, 42855292.
  • Davis, T.A., Grillo-López, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. & Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 31353143.
  • Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P., Cornillet-LeFebvre, P., Escoffre-Barbe, M., Maisonneuve, H., Delwail, V., Gressin, R., Legouffe, E., Vilque, J. P., Desablens, B., Jaubert, J., Ramee, J.F., Jenabian, A., Thyss, A., Le Pourhiet-Le Mevel, A., Travade, P., Delepine, R., Colombat, P & GOELAMS. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood, 105, 38173823.
  • Dogan, A., Du, M.Q., Aiello, A., Diss, T.C., Ye, H.T., Pan, L.X. & Isaacson, P.G. (1998) Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood, 91, 47084714.
  • Eich, H.T., Heimann, M., Stützer, H., Kriz, J., Reiser, M. & Müller, R.P. (2009) Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin’s lymphomas treated with radiation therapy. Strahlentherapie und Onkologie, 185, 288295.
  • Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrota, A., Kim, S., Alavi, A. & Schuster, S.J. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, 38753876.
  • Eshoa, C., Perkins, S., Kampalath, B., Shidham, V., Juckett, M. & Change, C.C. (2001) Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. American Journal of Clinical Pathology, 115, 862867.
  • Federico, M., Vitolo, U., Zinzani, P.L., Chisesi, T., Clò, V., Bellesi, G., Magagnoli, M., Liberatir, M., Boccomini, C., Niscola, P., Pavone, V., Cuneo, A., Santini, G., Brugiatelli, M., Baldini, L., Rigacci, L. & Resegotti, L. (2000) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood, 95, 783789.
  • Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., Cortelazzo, S., Martinelli, G., Martelli, M., Rigacci, L., Arcaini, L., Di Raimondo, F., Merli, F., Sabattini, E., McLaughlin, P. & Solal-Céligny, P. (2009a) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology, 27, 45554562.
  • Fellbaum, C., Sträter, J. & Hansmann, M.L. (1993) Follicular dendritic cells in extranodal non-Hodgkin lymphomas of MALT and non-MALT type. Virchows Archive A: Pathological Anatomy and Histology, 423, 335341.
  • Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.W. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 84478452.
  • Foran, J.M., Apostolidis, J., Papamichael, D., Norton, A.J., Matthews, J., Amess, J.A., Lister, T.A. & Rohatiner, A.Z. (1998) High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Annals of Oncology, 9, 865869.
  • Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hänel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Böck, H.P., Wandt, H., Unterhalt, M., Hiddemann, W and German Low-Grade Lymphoma Study Group. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 30643071.
  • Forstpointner, R., Unterhalt, M., Dreyling, M., Böck, H.P., Repp, R., Wandt, H., Pott, C., Seymour, J.F., Metzner, B., Hänel, A., Lehmann, T., Hartmann, F., Einsele, H., Hiddemann, W. & German Low Grade Lymphoma Study Group (GLSG). (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, 40034008.
  • Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., Fayad, L.E., Bessudo, A., Camacho, E.S., Williams, M.E., van der Jagt, R.H., Oliver, J.W. & Cheson, B.D. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology, 26, 204210. Erratum in: J Clin Oncol, 26, 1911.
  • Friedberg, J.W., Taylor, M.D., Cerhan, J.R., Flowers, C.R., Dillon, H., Farber, C.M., Rogers, E.S., Hainsworth, J.D., Wong, E.K., Vose, J.M., Zelenetz, A.D. & Link, B.K. (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology, 27, 12021208.
  • Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood, 103, 44164423.
  • Giné, E., Montoto, S., Bosch, F., Arenillas, L., Mercadal, S., Villamor, N., Martinez, A., Colomo, L., Campo, E., Monsterrat, E. & López-Guillermo, A. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Annals of Oncology, 17, 15391545.
  • Gordon, L.I., Witzig, T., Molina, A., Czuczman, M., Emmanouilides, C., Joyce, R., Vo, K., Theuer, C., Pohlman, B., Bartlett, N., Wiseman, G., Darif, M. & White, C. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clinical Lymphoma, 5, 98101.
  • Gordon, L.N., Grow, W.B., Pusateri, A., Douglas, V., Mendenhall, N.P. & Lynch, J.W. (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. Journal of Clinical Oncology, 23, 10961102.
  • Gu, K., Chan, W.C. & Hawley, R.C. (2008) Practical detection of t(14;18)(IgH/BCL2) in follicular lymphoma. Archives of Pathology and Laboratory Medicine, 132, 13551361.
  • Guadagnolo, B.A., Li, S., Neuberg, D., Ng, A., Hua, L., Silver, B., Stevenson, M.A. & Mauch, P. (2006) Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. International Journal of Radiation Oncology Biology Physics, 64, 928934.
  • Haas, R.L., Poortmans, P., De Jong, D., Aleman, B.M., Dewit, L.G., Verheij, M., Hart, A.A., Van Oers, M.H., Van Der Hulst, M., Baars, J.W. & Bartelink, H. (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. Journal of Clincial Oncology, 21, 24742480.
  • Haas, R.L., Poortmans, P., De Jong, D., Verheij, M., Van Der Hulst, M., De Boer, J.P. & Bartelink, H. (2005) Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. European Journal of Cancer, 41, 17241730.
  • Hagenbeek, A., Eghbali, H., Monfardini, S., Vitolo, U., Hoskin, P.J., De Wolf-Peeters, C., MacLennan, K., Staab-Renner, E., Kalmus, J., Schott, A., Teodorovic, I., Negrouk, A., Van Glabbeke, M. & Marcus, R. (2006) Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 24, 15901596.
  • Hainsworth, J.D., Litchy, S., Shaffer, D.W., Lackey, V.L., Grimaldi, M. & Greco, F.A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 23, 10881095.
  • Hari, P., Carreras, J., Zhang, M.J., Gale, R.P., Bolwell, B.J., Bredeson, C.N., Burns, L.J., Cairo, M.S., Freytes, C.O., Goldstein, S.C., Hale, G.A., Inwards, D.J., Lemaistre, C.F., Maharaj, D., Marks, D.I., Schouten, H.C., Slavin, S., Vose, J.M., Lazarus, H.M. & Van Besien, K. (2008) Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biology of Blood and Marrow Transplantation, 14, 236245.
  • Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dölken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., Von Grünhagen, U. & East German Study Group Haematology and Oncology Study. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 986992.
  • Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Resier, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermarcher, H., Trümper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 37253732.
  • Hochster, H.E.W., Gascoyne, R.D., Ryan, T.S., Habermann, T.M., Gordon, L.E., Frankel, S.R. & Horning, S.J. (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood, 106, 349.
  • Horning, S.J. & Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. New England Journal of Medicine, 311, 14711475.
  • Hutchings, M. & Barrington, S.F. (2009) PET/CT for therapy response assessment in lymphoma. Journal of Nuclear Medicine, 50(Suppl 1), 21S30S.
  • Ingram, W., Devereux, S., Das-Gupta, E.P., Russell, N.H., Haynes, A.P., Byrne, J.L., Shaw, B.E., McMillan, A., Gonzalez, J., Ho, A., Mufti, G.J. & Pagliuca, A. (2008) Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. British Journal of Haematology, 141, 235243.
  • Janikova, A., Bolcak, K., Pavlik, T., Mayer, J. & Kral, Z. (2008) Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clinical Lymphoma & Myeloma, 8, 287293.
  • Jerusalem, G., Beguin, Y., Naijar, F., Hustinx, R., Fassotte, M.F., Rigo, P. & Fillet, G. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Annals of Oncology, 12, 825830.
  • Jóhannsson, J., Specht, L., Mejer, J. & Jensen, B.A. (2002) Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. International Journal of Radiation Oncology Biology Physics, 54, 14661470.
  • Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A., Cheson, B.D. & Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 25, 571578.
  • Kahl, B.S., Bartlett, N.L., Leonard, J.P., Chen, L., Ganjoo, K., Williams, M.E., Czuczman, M.S., Robinson, K.S., Joyce, R., van der Jagt, R.H. & Cheson, B.D. (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer, 116, 106114.
  • Kaminski, M.S., Tuck, M., Estes, J., Kolstad, A., Ross, C.W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S. & Wahl, R.L. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. New England Journal of Medicine, 352, 441449.
  • Karam, M., Novak, L., Cyriac, J., Ali, A., Nazeer, T. & Nugent, F. (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer, 107, 175183.
  • Katzenberger, T., Ott, G., Klein, T., Kalla, J., Müller-Hermelink, H.K. & Ott, M.M. (2004) Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. American Journal of Pathology, 165, 481490.
  • Khouri, I.F., McLaughlin, P., Saliba, R.M., Hosing, C., Korbling, M., Lee, M.S., Medeiros, L.J., Fayad, L., Samaniego, F., Alousi, A., Anderlini, P., Couriel, D., De Lima, M., Giralt, S., Neelapu, S.S., Ueno, N.T., Samuels, B.I., Hagemeister, F., Kwak, L.W. & Champlin, R.E. (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 111, 55305536.
  • Kimby, E., Björkholm, M., Gahrton, G., Glimelius, B., Hagberg, H., Johansson, B., Johansson, H., Juliusson, G., Järnmark, M., Löfvenberg, E., Killander, A., Lerner, R., Lindemalm, C., Pettersson, U., Robert, K.H., Simonsson, B., Stalfelt, A.M., Sundstrom, C., Svedmyr, E., Uden, A.M., Wadman, B., Wahlin, A., Ost, A. & Mellstedt, H. (1994) Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology, 5(Suppl 2), S67S71.
  • Klapper, W., Hoster, E., Rölver, L., Schrader, C., Janssen, D., Tiemann, M., Bernd, H.W., Determann, O., Hasnmann, M.L., Möller, P., Feller, A., Stein, H., Wacker, H.H., Dreyling, M., Unterhalt, M., Hiddemann, W., Ott, G. & German Low Grade Lymphoma Study Group. (2007) Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. Journal of Clinical Oncology, 25, 33303336.
  • Kornacker, M., Stumm, J., Pott, C., Dietrich, S., Süssmilch, S., Hensel, M., Nickelsen, M., Witzens-harig, M., Kneba, M., Schmitz, N., Ho, A.D. & Dreger, P. (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Annals of Oncology, 20, 722728.
  • Kwee, T.C., Kwee, R.M. & Nievelstein, R.A. (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood, 111, 504516.
  • Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H., Freund, M., Hess, G., Truemper, L., Diehl, V., Kropff, M., Kneba, M., Schmitz, N., Metzner, B., Pfirrmann, M., Unterhalt, M., Hiddemann, W. & German Low-Grade Lymphoma Study Group. (2004a) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German low-grade lymphoma study group. Blood, 104, 26672674.
  • Lenz, G., Dreyling, M., Schiegnitz, E., Haferlach, T., Hasford, J., Unterhalt, M. & Hiddemann, W. (2004b) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group. Journal of Clinical Oncology, 22, 49264933.
  • Leonard, R.C., Hayward, R.L., Prescott, R.J. & Wang, J.X. (1991) The identification of discrete prognostic groups in low grade non-Hodgkin’s lymphoma. The Scotland and Newcastle lymphoma group therapy working party. Annals of Oncology, 2, 655662.
  • Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F.B., Ayers, G.D., Hess, M., Romaguera, J., Rodriguez, M.A., Tsimberidou, A.M., Verstovsek, S., Younes, A., Pro, B., Lee, M.S., Ayala, A. & McLaughlin, P. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson cancer center. Journal of Clinical Oncology, 24, 15821589.
  • Ljungman, P., Urbano-Ispizua, A., Cavazzana-Calvo, M., Demirer, T., Dini, G., Einsele, H., Gratwohl, A., Madrigal, A., Niederwieser, D., Passweg, J., Rocha, V., Saccardi, R., Schouten, H., Schmitz, N., Socie, G., Surega, A., Apperley, J. & European Group for Bone and Marrow. (2006) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplantation, 37, 439449.
  • López-Guillermo, A., Montserrat, E., Bosch, F., Terol, M.J., Campo, E. & Rozman, C. (1994) Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. Journal of Clinical Oncology, 12, 13431348.
  • Luthy, S.K., Ng, A.K., Silver, B., Degnan, K.O., Fisher, D.C., Freedman, A.S. & Mauch, P.M. (2008) Response to low-dose involved-field radiotherapy in patients with non-Hodgkin’s lymphoma. Annals of Oncology, 19, 20432047.
  • MacManus, M.P. & Hoppe, R.T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University Journal of Clinical Oncology, 14, 12821290.
  • Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 14171423.
  • Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cuningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 45794588.
  • McLaughlin, P., Grillo- López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Montoto, S., López-Guillermo, A., Altés, A., Perea, G., Ferrer, A., Camós, M., Villela, L., Bosch, F., Esteve, J., Cervantes, F., Bladé, J., Nomdedeu, B., Campo, E., Sierra, J. & Montserrat, E. (2004) Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Annals of Oncology, 15, 14841489.
  • Montoto, S., Davies, A.J., Matthews, J., Calaminici, M., Norton, A.J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A.Z. & Lister, T.A. (2007a) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. Journal of Clinical Oncology, 25, 24262433.
  • Montoto, S., Canals, C., Rohatiner, A.Z., Taghipour, G., Sureda, A., Schmitz, N., Gisselbrecht, C., Fouillard, L., Milipied, N., Haioun, C., Slavin, S., Conde, E., Fruchart, C., Ferrant, A., Leblond, V., Tilly, H., Lister, T.A., Goldstone, A.H. & EBMT Lymphoma Working Party. (2007b) Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia, 21, 23242331.
  • Moog, F., Bangerter, M., Diederichs, C.G., Guhlann, A., Kotzerke, J., Merkle, E., Kolokythas, O., Herrmann, F. & Reske, S.N. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 203, 795800.
  • Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 38653871.
  • Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P.C., Kolstad, A., D’Amore, F., Gonzalez Diaz, M., Petrini, M., Sebban, C., Zinzani, P.L., Van Oers, M.H., Van Putten, W., Bischof-Delaloye, A., Rohatiner, A., Salles, G., Kuhlmann, J. & Hagenbeek, A. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Journal of Clinical Oncology, 26, 51565164.
  • Morschhauser, F., Mounier, N., Sebban, C., Brice, P., Solal-Celigny, P., Tilly, H., Feugier, P., Fermé, C., Copin, M.C. & Lamy, T. (2010) Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d’Etude des Lymphomes de l’Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). Cancer, 116, 42994308.
  • Murthy, V., Thomas, K., Foo, K., Cunningham, D., Johnson, B., Norman, A. & Horwich, A. (2008) Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clinical Lymphoma & Myeloma, 8, 241245.
  • Naresh, K.N. (2008) Nodal marginal zone B-cell lymphoma with prominent follicular colonization – difficulties in diagnosis: a study of 15 cases. Histopathology, 52, 331339.
  • Newman, J.S., Francis, I.R., Kaminski, M.S. & Wahl, R.L. (1994) Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology, 190, 111116.
  • Peterson, B.A., Petroni, G.R., Frizzera, G., Barcos, M., Bloomfield, C.D., Nissen, N.I., Hurd, D.D., Henderson, E.S., Sartiano, G.P., Johnson, J.L., Holland, J.F. & Gottlieb, A.J. (2003) Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 21, 515.
  • Pettengell, R., Schmitz, N., Gisselbrecht, C., Caballero, D., Colombat, P., Conde, E., Metzner, B., Walewski, J., Geisler, C., Goldstone, A. & for the European Group for Blood ad Marrow Transplantation (2010) Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. Journal of Clinical Oncology, (ASCO Meeting Abstracts) 28 No 15 (May 20 Supplement).
  • Plancarte, F., López-Guillermo, A., Arenillas, L., Montoto, S., Giné, E., Muntañola, A., Ferrer, A., Villamor, N., Bosch, F., Colomo, L., Balaguer, O., Campo, E. & Montserrat, E. (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the follicular lymphoma international prognostic index to predict the outcome of patients. European Journal of Haematology, 76, 5863.
  • Press, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., Leblanc, M., Gaynor, E.R., Rivkin, S.E. & Fisher, R.I. (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood, 102, 16061612.
  • Pugh, T.J., Ballonoff, A., Newman, F. & Rabinovitch, R. (2010) Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer, 15, 38433851.
  • Reddy, S., Saxena, V.S., Pellettiere, E.V. & Hendrickson, F.R. (1989) Stage I and II non-Hodgkin’s lymphomas: long-term results of radiation therapy. International Journal of Radiation Oncology Biology Physics, 16, 687692.
  • Rezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R. & Maloney, D.G. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 26, 211217.
  • Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., De Elvira, C.R., Taghipour, G., Schmitz, N. & Lymphoma Working Party of the European Group for Blood and Bone Marrow Translplantation. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the European group for blood and bone marrow transplantation. Blood, 100, 43104316.
  • Robinson, K.S., Williams, M.E., van der Jagt, R.H., Cohen, P., Herst, J.A., Tulpule, A., Schwartzberg, L.S., Lemieux, B. & Cheson, B.D. (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 26, 44734479.
  • Rohatiner, A.Z., Gregory, W.M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R.I., Unterhalt, M., Arranz, R., Chisesi, T., Aviles, A. & Lister, T.A. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. Journal of Clinical Oncology, 23, 22152223.
  • Rohatiner, A.Z., Nadler, L., Davies, A.J., Apostolidis, J., Neuberg, D., Matthews, J., Gribben, J.G., Mauch, P.M., Lister, T.A. & Freedman, A.S. (2007) Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. Journal of Clinical Oncology, 25, 25542559.
  • Romaguera, J.E., McLaughlin, P., North, L., Dixon, D., Silvermintz, K.B., Garnsey, L.A., Velasquez, W.S., Hagemeister, F.B. & Cabanillas, F. (1991) Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. Journal of Clinical Oncology, 9, 762769.
  • Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, A., von Gruenhagen, U., Losem, C., Heil, G., Welslau, M., Bahlser, C., Kaiser, U., Ballo, H., Weidmann, E., Duerk, H., Kofahl-Krause, D., Roller, F., Barth, J., Hoelzer, D., Hinke, A. & Brugger, W. (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (study group indolent lymphomas, Germany). Blood (ASH Annual Meeting Abstracts), 114, 11. (Abstract 405).
  • Sacchi, S., Pozzi, S., Marcheselli, R., Federico, M., Tucci, A., Merli, F., Orsucci, L., Liberati, M., Vallisa, D., Brugiatelli, M. & Italian Lymphoma Study Group. (2007) Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer, 110, 121128.
  • Saikia, U.N., Dey, P., Saikia, B. & Das, A. (2002) Fine-needle aspiration biopsy in diagnosis of follicular lymphoma: cytomorphologic and immunohistochemical analysis. Diagnostic Cytopathology, 26, 251256.
  • Salles, G., Mounier, N., De Guibert, S., Morschhauser, F., Doyen, C., Rossi, J.F., Haioun, C., Brice, P., Mahé, B., Bouabdallah, R., Audhuy, B., Ferme, C., Dartigeas, C., Feugier, P., Sebban, C., Xerri, L. & Foussard, C. (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood, 112, 48244831.
  • Salles, G., Seymour, J.F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Fermé, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 4251. Erratum in: Lancet, 377, 1154.
  • Sawyer, E.J. & Timothy, A.R. (1997) Low dose palliative radiotherapy in low grade non-Hodgkin’s lymphoma. Radiotherapy & Oncology, 42, 4951.
  • Schouten, H.C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnson, H.E., Doorduijn, J.K., Sydes, M.R. & Kvalheim, G. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology, 21, 39183927.
  • Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M. & Engert, A. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. Journal of the National Cancer Institute, 99, 706714.
  • Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P., Haioun, C., Tilly, H., Feugier, P., Bouabdallah, R., Doyen, C., Salles, G. & Coiffier, B. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood, 108, 25402544.
  • Seymour, J.F., Pro, B., Fuller, L.M., Manning, J.T., Hagemeister, F.B., Romaguera, J., Rodriguez, M.A., Ha, C.S., Smith, T.L., Ayala, A., Hess, M., Cox, J.D., Cabanillas, F. & McLaughlin, P. (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 21, 21152122.
  • Solal-Céligny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Bertrand Coiffier, X. & Christian Gisselbrecht for the Groupe d’Etude des Lymphomes de l’Adulte (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. New England Journal of Medicine, 329, 16081614.
  • Solal-Céligny, P., Lepage, E., Brousse, N., Tendler, C.L., Brice, P., Haïoun, C., Gabarre, J., Pignon, B., Tertian, G., Bouabdallah, R., Rossi, J.F., Doyen, C. & Coiffier, B. (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. Journal of Clinical Oncology, 16, 23322338.
  • Solal-Céligny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haïoun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 12581265.
  • Soubeyran, P., Eghbali, H., Trojani, M., Bonichon, F., Richaud, P. & Hoerni, B. (1996) Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center Annals of Oncology, 7, 713718.
  • Stumpe, K.D., Urbinelli, M., Steinert, H.C., Glanzmann, C., Buck, A. & Von Schulthess, G.K. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. European Journal of Nuclear Medicine, 25, 721728.
  • Swenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman-Hoffman, V.L., Chrischilles, E. & Link, B.K. (2005) Improved survival of follicular lymphoma patients in the United States. Journal of Clinical Oncology, 23, 50195026.
  • Swerdlow, S., Campo, E., Harris, N.L., Jaffe, E., Pileri, S., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Geneva, World Health Organization.
  • Symmers, D. (1927) Follicular lymphadenopathy with splenomegaly: a newly recognized disease of the lymphatic system. Archives of Pathology, 3, 816820.
  • The Non-Hodgkin’s Lymphoma Classification Project. (1997) A clinical evaluation of the international. Lymphoma study group classification of non-. Hodgkin’s lymphoma. Blood, 89, 39093918.
  • Thomson, K.J., Morris, E.C., Milligan, D., Parker, A.N., Hunter, A.E., Cook, G., Bloor, A.J., Clark, F., Kazmi, M., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. Journal of Clinical Oncology, 28, 36953700.
  • Trotman, J., Fournier, M., Lamy, T., Estell, J., Sonet, A., Janikova, A., Tilly, H., Decaudin, D., Gabarre, J., Seymour, J., Garin, E., Forsyth, C., Fulham, M., Vander Borght, T., Shpilberg, O. & Salles, G. (2010) Result of FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent prognostic indicator of outcome for patients with follicular lymphoma: an analysis from the PRIMA study. Blood (ASH Annual Meeting Abstracts), 116, 855.
  • Tsimberidou, A.M., McLaughlin, P., Younes, A., Rodriguez, M.A., Hagemeister, F.B., Sarris, A., Romaguera, J., Hess, M., Smith, T.L., Yang, Y., Ayala, A., Preti, A., Lee, M.S. & Cabanilla, F. (2002) Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood, 100, 43514357.
  • Tzankov, A., Hittmair, A., Müller-Hermelink, H.K., Rüdiger, T. & Dirnhofer, S. (2002) Primary gastric follicular lymphoma with parafollicular monocytoid B-cells and lymphoepithelial lesions, mimicking extranodal marginal zone lymphoma of MALT. Virchows Archive, 441, 614617.
  • Vajdic, C.M., Van Leeuwen, M.T., Turner, J.J., McDonald, A.M., Webster, A.C., McDonald, S.P., Chapman, J.R., Kaldor, J.M. & Grulich, A.E. (2010) No excess risk of follicular lymphoma in kidney transplant and HIV-related immunodeficiency. International Journal of Cancer, 127, 27322735.
  • Van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van’t Veer, M., Vranovsky, A., Holte, H., Van Glabbeke, M., Teodorovic, I., Rozewicz, C. & Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 32953301.
  • Velasquez, W.S., Lew, D., Grogan, T.M., Spiridonidis, C.H., Balcerzak, S.P., Dakhil, S.R., Miller, T.P., Lanier, K.S., Chapman, R.A., Fisher, R.I. & Southwest Oncology Group. (2003) Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. Journal of Clinical Oncology, 21, 19962003.
  • Vigouroux, S., Michallet, M., Porcher, R., Attal, M., Ades, L., Bernard, M., Blaise, D., Tabrizi, R., Garban, F., Cassuto, J.P., Chevalier, P., Facon, T., Ifrah, N., Renaud, M., Tilly, H., Vernant, J.P., Kuentz, M., Bourhis, J.H., Bordigoni, P., Deconinck, E., Lioure, B., Socié, G., Milpied, N. & French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). (2007) Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French society of bone marrow graft transplantation and cellular therapy (SFGM-TC). Haematologica, 92, 627634.
  • Wilder, R.B., Jones, D., Tucker, S.L., Fuller, L.M., Ha, C.S., McLaughlin, P., Hess, M.A., Cabanillas, F. & Cox, J.D. (2001) Long-term results with radiotherapy for stage I-II follicular lymphomas. International Journal of Radiation Oncology Biology Physics, 51, 12191227.
  • Williams, C.D., Harrison, C.N., Lister, T.A., Norton, A.J., Blystad, A.K., Coiffier, B., Taghipour, G., Schmitz, N., Goldstone, A.H. & European Bone Marrow Transplant Lymphoma Working Party. (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European bone marrow transplant registry. Journal of Clinical Oncology, 19, 727735.
  • Wirth, A., Foo, M., Seymour, J.F., Macmanus, M.P. & Hicks, R.J. (2008) Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. International Journal of Radiation Oncology Biology Physics, 71, 213219.
  • Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olenik, T., Multani, P.S. & White, C.A. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 20, 32623269.
  • Wöhrer, S., Jaeger, U., Kletter, K., Becherer, A., Hauswirth, A., Turetschek, K., Raderer, M. & Hoffmann, M. (2006) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Annals of Oncology, 17, 780784.
  • Young, R.C., Longo, D.L., Glatstein, E., Ihde, D.C., Jaffe, E.S. & DeVita, Jr, V.T.. (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars in Haematology, 25, 1116.
  • Yuen, A.R., Kamel, O.W., Halpern, J. & Horning, S.J. (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. Journal of Clinical Oncology, 13, 17261733.